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BACKGROUND: Quantitative T2 and diffusion MRI indices inform about tissue state and 
microstructure, both of which may be affected by pathology before tissue atrophy. 
PURPOSE: To evaluate the capability of both volumetric and quantitative MRI (qMRI) of the 
hippocampus and entorhinal cortex (EC) for classification of amnestic mild cognitive 
impairment (aMCI) and Alzheimer’s disease dementia (ADD).  
STUDY TYPE: Retrospective cross-sectional study.  
POPULATION: Consecutive cohorts of healthy age-matched controls (n=62), aMCI patients 
(n=25) and ADD patients (n=14). 
FIELD STRENGTH AND SEQUENCE: 3T using T1-weighted imaging, T2-weighted imaging, 
T2 relaxometry and diffusion tensor imaging (DTI). 
ASSESSMENT: Montreal Cognitive Assessment (MoCA) and paired associate learning (PAL) 
tests for cognitive state. Hippocampal subfield volumes by the automated segmentation of 
hippocampal subfields system from structural brain images. T2 relaxation time and DTI indices 
quantified for hippocampal subfields. The fraction of voxels with high T2 values (>20 ms above 
subfield median) was calculated and regionalised for hippocampus and EC.  
STATISTICAL TESTS: Support vector machine (SVM) and receiver operating characteristic 
(ROC) analyses from cognitive and MRI data.  
RESULTS: Quantitative MRI classified aMCI and ADD with excellent sensitivity (79.0% and 
94.5%, respectively) and specificity (85.6% and 86.1%, respectively), superior to volumes 
alone (70.0% and 84.5% for respective sensitivities; 82.2 and 91.1 for respective specificities) 
and similar to cognitive tests (61.7% and 87.5% for respective sensitivities; 88.2% and 90.7% 
for respective specificities). Regions of high T2 are dispersed throughout each hippocampal 
subfield in aMCI and ADD with higher concentration than controls, and was most pronounced 
in the EC. No other individual qMRI marker than EC volume can separate aMCI from ADD, 
however.  
DATA CONCLUSION: Quantitative MRI markers of hippocampal and entorhinal tissue states 
are sensitive and specific classifiers of aMCI and ADD. They may serve as markers of a 
neurodegenerative state preceding volume loss. 
KEYWORDS: T2 relaxometry, diffusion tensor imaging, hippocampus, mild cognitive 
impairment, Alzheimer’s disease dementia 
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INTRODUCTION 
The most common form of dementia is Alzheimer’s disease dementia (ADD), which may be 
preceded by a prodromal phase of mild cognitive impairment (MCI), although MCI does not 
imply AD as an eventuality (1). There is considerable interest in early detection of ADD by 
imaging. This is made challenging by its clinical presentation being retarded as compared to 
its pathology (2), and by the pathology being difficult to detect in vivo (3). The importance of 
early detection is driven by several factors. Firstly, it is generally thought that any novel 
intervention is more likely to arrest development of ADD rather than reverse it (4). Secondly, 
and with the first point in mind, developing any such intervention will not be straightforward 
without the ability to recruit participants at a sufficiently early stage to validate that intervention. 
Likely to reflect inadequate inclusion of participants, 172 human trials on dementia drugs failed 
up to 2008 (5), considerably exceeding the average rate of failure of clinical trials in general 
(6).  
Commonly used diagnostic strategies are dominated by assessment of memory and 
behavioral symptoms and use of a “structural” imaging modality typically to make an 
assessment of gross brain structure and tissue loss (2). Specific molecular imaging (3) or 
cerebrospinal fluid biomarker measurement are rarely available in clinical practice (7). Atrophy 
is not a direct marker of pathology per se, but of the consequence of pathology. The 
characterisation of brain structure and atrophy has nevertheless proved useful in 
demonstrating the existence of a spectrum of types of dementia and states, and in monitoring 
disease progression (2,8,9). Widespread cortical thinning is generally seen in ADD, as well as 
hippocampal atrophy, with the rate of atrophy being generally increased in ADD. However, 
there are several distinct patterns of atrophy observable, and no single structural biomarker of 
ADD. Hippocampal atrophy, or its rate, adds confidence in diagnosis, but hippocampal atrophy 
is absent in 11% of ADD cases (8). Nevertheless, structural imaging, preferably by MRI, is 
recommended in all patients by the UK National Institute of Clinical Excellence (NICE) and 
therefore is a modality that could be further exploited with minimal extra cost per patient (10). 
 
Diffusion tensor imaging (DTI) provides various indices whose values are determined by the 
microstructural features of tissues. It has been reported that fractional anisotropy (FA) is 
decreased and mean diffusivity increased in the hippocampus in ADD (9,11). The pathology 
of ADD is widespread, and includes white matter (WM). DTI has also provided evidence of 
microstructural tissue alteration in ADD in WM (9,11,12), and that WM changes in tissue state 
may be observed by DTI before atrophy (13-15). T2 relaxometry studies have reported either 
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shortened (16), normal (17) or prolonged  (18,19) numeric values for T2 in hippocampi of ADD 
patients. 
Our objectives in this study were to examine the utility of quantitative MRI (in particular T2 
relaxometry and DTI) as a non-invasive assay of the tissue state of hippocampal subfields and 
the entorhinal cortex (EC), structures know to be affected by early AD pathology (20), with a 
view to detecting differences in tissue state between healthy older controls, persons with MCI 
and those with ADD to as a spectrum of clinical presentation for AD. In the healthy older 
population, there will be relatively few people with significant AD pathology (21) and in the 
ADD group we expect almost all participants to have AD pathology, although one should bear 
in mind that patients here were diagnosed using standard clinical tests and diagnostic 
accuracy is around 70-90% (22). The aMCI group are more heterogenous and we know that 
at least around 50% will develop ADD, but others will remain stable and are presumed not to 
have AD pathology (23). In order to guide early diagnosis, we are particularly interested in 
tests that will differentiate between the healthy control group and participants with MCI (with 
more variability in the MCI group). Therefore, in particular, we consider the following three 
hypotheses: 
First, quantitative T2 and diffusivity distributions of hippocampal subfields and the EC, by virtue 
of the transition to a neurodegenerative state preceding (or concurrent with) atrophy in aMCI 
and ADD, will differ according to clinical state of the disease. The transition to a 
neurodegenerative state will lead to a more heterogeneous microstructural environment, 
measurable by increased widths of T2 and diffusivity distributions, equivalent to the statement 
that a greater proportion of voxels will deviate from a state representative of healthy tissue in 
non-healthy individuals. Second, quantitative MRI, by virtue of sensitivity to tissue quality 
rather than quantity, will have different or independent capacity to classify clinical state of the 
disease to tissue quantity. Quantitative biomarkers of tissue state will therefore be de-
correlated from volume. Third, the distinct distributions of compromised tissue state in different 
limbic system components will confer distinct T2 distributions on each. Improved capacity to 
classify clinical state of the disease will be obtained by making separate use of T2 distributions 
from each component, the classifier otherwise having to absorb variance due to cell viability. 
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METHODS AND MATERIALS 
Participant cohort 
We analysed the first 101 volunteer participants, recruited as part of the institutional 
hippocampal imaging study, where longitudinal data collection is ongoing. 62 were healthy 
controls with no known brain disorder (38 female, age range 49 to 87, mean age 68), 25 were 
aMCI (12 female, age range 51 to 88, mean age 73), and 14 were ADD patients (10 female, 
age range 56 to 89, mean age 72). 
Amnestic MCI diagnosis was based on the criteria given by Petersen et al (24) and, for 
inclusion, all participants had to have symptoms of memory impairment and/or be 1 standard 
deviation below that expected on a memory test. Thus, we have included both amnesic MCI 
and multidomain MCI patients where amnesia as a significant feature. Participants underwent 
the paired associative learning (PAL) task of the CANTAB toolbox (25) and the Montreal 
Cognitive Assessment (MoCA). Cognitive testing was within 6 weeks of MRI. All participants 
gave informed consent and ethical approval was granted by the Institutional Review Board. 
Image acquisition 
All imaging was performed using a Siemens Magnetom Skyra 3T system equipped with a 
parallel transmit body coil and 32-channel head receiver array coil. The imaging protocol 
comprised a 3D T1-weighted MPRAGE, 2D multi-contrast spin-echo and 2D DTI with the 
following parameters: MPRAGE: coronal, TR 2200 ms, TE 2.42 ms, TI 900 ms, flip angle 9°, 
acquired resolution 0.68 x 0.68 x 1.60 1.60 mm3, acquired matrix size 152 x 320 x 144, 
reconstructed resolution 0.34 x 0.34 x 1.60 mm3 (after 2-fold interpolation in-plane by zero-
filling in k-space), reconstructed matrix size 540 x 640 x 144, GRAPPA factor 2 (26), time 5:25 
min. Multi-contrast spin-echo: TR 4500 ms, TE 12 ms, number of echoes 10, echo spacing 12 
ms acquired resolution 0.68 x 0.68 x 1.7 mm3 inclusive of 15% slice gap, acquired matrix size 
152 x 320, 34 slices, interleaved slice order, reconstructed resolution 0.34 x 0.34 x 1.7 mm3 
(after 2-fold interpolation in-plane by zero-filling in k-space, and inclusive of 15% slice gap), 
reconstructed matrix size 540 x 640, 34 slices, GRAPPA factor 2, time 11:07 min. DTI: axial, 
TR 3800 ms, TE 85.2 ms, b-value 1000 s/mm2, number of gradient directions 60 (full-sphere), 
acquired and reconstructed resolution 2 x 2 x 2 mm3 inclusive of 10% slice gap, matrix size 
122 x 122, 60 slices, GRAPPA factor 2, multi-band factor 2 (27), time 4:30 min.  Note that the 
multi-echo spin echo did not have full-brain coverage, its anterior-posterior coverage only 
extending around 1 cm anterior and posterior to the head and tail of the hippocampus 
respectively, with the acquisition tilted such that the hippocampal body created an axis normal 
to the slice acquisition plane. 
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Image processing 
Diffusion tensors were fitted using DTIFIT after eddy current correction using the 
EDDY_CORRECT program of FSL (28). T2 maps were computed by a voxel-wise fit of a 
mono-exponential function in a logarithmic space, excluding the first echo. This was done 
since the pulse sequence allows the passage of both spin and stimulated echoes due to the 
use of identical crusher gradients astride each refocusing pulse, though the first echo contains 
only spin echo contributions. A single T2-weighted image was prepared by summing over the 
echo times. 
Hippocampal subfield boundaries were demarcated using the software package ASHS (29). 
This requires a T1-weighted and T2-weighted input, of which the T2-weighted input must have 
sufficient resolution in the coronal plane for subfield boundary demarcation and dimensions 
ordered with the AP dimension the 3rd dimension. These criteria were fulfilled by the sum-over-
echoes image, with dimensions permuted using FSL SWAPDIM. The T1-weighted image was 
typically provided without brain extraction and the T2-weighted image with brain-extraction. 
All ASHS masks were visually inspected and if low quality was evident, the T1-weighted image 
was brain-extracted using the VBM8 toolbox of SPM8, and the sum-over-echoes T2-weighted 
image also corrected for bias field using FSL FAST. Typical set of TE series images and 
corresponding echo summed T2-weigthed images and T2 and R2 maps are shown in 
Supplementary Information (SI, Figure S1). All TE series were visually inspected for possible 
motion artefacts, if motion was evident, the case was excluded. Signal-to-noise ratios (SNR) 
for volumes encompassing hippocampi from TE=24ms and TE=120ms images are given in SI 
(Figure S1). Volumes of subfields as well as T2 distribution statistics were calculated directly 
from these masks and by applying them to the T2 maps. Using Matlab toolbox T2 distributions 
were fitted into Burr function to determine median average distribution. Potential effect of 
Gaussian noise on T2 Burr distribution was addressed by simulations (Figure S2). The 
conclusion from the simulations is that T2 Burr distribution is not influenced by Gaussian noise, 
rather noise would convert the T2 distribution to close-to-Gaussian, which was not observed 
in the current data set. For each subfield, as well as the whole hippocampus and EC, masks 
of “high T2” voxels were also prepared, defined for a particular region as voxels for which the 
T2 was greater than 20 ms above the median T2 for that region. 20 ms was chosen for the 
filter as it is a good approximation to the average standard deviation of hippocampal T2 for a 
healthy participant at age 60 (Figure S3), thus, voxels within the filter capture ~95% of 
observations for healthy participants aged 60 or younger. 
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To regionalize where T2 was likely to be elevated within a group (control, aMCI, or ADD) within 
each hippocampal subfield, or in the EC, the masks were required in a common template 
space, for which we used the MNI space. T2-weighted images were registered to T1-weighted 
images using a rigid-body transformation with FSL FLIRT, and T1-weighted images registered 
non-linearly to the MNI template using FSL FNIRT. The probability of a voxel having a T2 
outside the filter could then be obtained simply by summing the high-T2 masks and dividing 
by the number of participants. This was done for each participant group and each subfield 
separately. Image data processing pipeline is presented in Figure 1. 
DTI images were registered to T2 space using FSL FLIRT. Whole-hippocampus statistics were 
calculated for the fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD) and 
axial diffusivity (AxD). Prior to applying the whole-hippocampus masks, they were eroded by 
1 voxel around the exterior to mitigate partial volume effects possible from the coarser 
resolution of the DTI acquisition. All image registrations were performed using FSL (30). 
Statistics 
The capability of sets of variables to classify cognitive groups was assessed by training 
support vector machine (SVM) classifiers (with 2nd order polynomial kernel), predicting 
posterior probabilities and computing receiver operating characteristics (ROC) with statistics 
and machine learning tool in Matlab. Due to the imbalanced group sizes, a cross-validation 
procedure was implemented to draw random samples of equal sizes from each group, with 
the sample size defined so as to be one smaller than the smallest group. 250 iterations were 
performed, and the mean ROC statistics were kept, with their standard deviations across the 
iterations used as uncertainties. This analysis was carried out for the following sets of 
variables: 1. Volumes: {CA1, CA3, dentate gyrus (DG), subiculum (SUB), whole_hippo, EC}; 
2. T2 median absolute deviations (T2mad): {cornu ammonis 1 (CA1), CA3, dentate gyrus 
(DG), subiculum (SUB), whole hippocampus (whole_hippo), EC}; 3. fraction of high-T2 voxels: 
{CA1, CA3, DG, SUB, whole_hippo, EC}; 4. DTI median absolute deviation (DTImad) across 
whole hippocampus: {FA, MD, RD, AxD}; 5. Cognitive variables: {MoCA_score, PAL_score, 
PAL_max_level, PAL_mean_reaction_time}. Sets 1,2,3 and 4 were then combined to an “all 
MRI” set. Sets 1, 3 and 5 were also combined to produce the best-performing set. In both 
former cases, due to the large set sizes, prior to SVM/ROC, principal component analysis 
(PCA) was performed, retaining the first 5 principal components only, to reduce the 
dimensionality and speed up classification with minimal information loss. 
Shapiro-Wilk tests for normality were performed on all MRI variables for each subfield. Where 
all groups were normally distributed, group differences in MRI parameters were assessed 
using one-way ANOVAs, with Tukey’s post-hoc test for pair-wise group comparisons. Where 
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tests for normality were not fully met, Independent Kruskal-Wallis Tests were used to assess 
group differences, with Dunn’s post-hoc test for pair-wise group comparisons. ROC 
comparisons were assessed with multiple t-tests, corrected for multiple comparisons using 
Benjamini-Krieger-Yekutieli method. All statistical analyses were performed using Matlab 
version 2016b (with statistics and machine learning toolbox), IBM SPSS Statistics v24 and 
GraphPad Prism v7.    
 
RESULTS 
Classifying groups with MRI and cognitive tests 
Table 1 shows statistical data for hippocampal subfields and EC volumes, T2mad, high-T2 
fraction and DTImad data. It is evident that while volumes, T2mad and high-T2 fraction were 
different in both aMCI and ADD patients relative to controls, however, none of the MRI 
measures were different between aMCI and ADD participants. 
Figure 2 shows the ROC curves for different sets of variables, using the group-balanced cross-
validation procedure. It is evident that most sets perform well, but often struggle for sensitivity 
of detection of aMCI, despite generally very good specificity for all groups. The combination 
of all MRI variables results in a classifier with very similar performance to the cognitive tests 
MoCA and PAL combined, and which out-performs these cognitive tests for sensitivity of 
detection of aMCI. The sets which had the best classifying power were combined on the 
premise that they should result in an optimal classifier, which indeed they did. The optimal 
classifier, combining PAL, MoCA, hippocampal subfield volumes and the subfield-wise 
fractions of high-T2 voxels accomplished the highest sensitivity for aMCI detection, and all 
other parameters either optimal or within the uncertainty bounds indistinguishable from 
optimal. 
Table 2 shows the ROC statistics for the different sets of variables. For separation of aMCI 
patients and controls all MRI variables (sets 1-4 combined) performed significantly better than 
volumes alone (set 1), as shown by Benjamini-Krieger-Yekutieli analysis for ROC curve 
metrics (Table S1). The optimum data set outperformed any of individual MRI set, but all MRI 
variables were as good as the optimum combination for aMCI cohort. In ADD patients 
quantitative MRI was similarly specific, with high-T2 fraction having superior sensitivity than 
volumes (Table 2).  
The inclusion of age did not improve classification accuracy. The use of statistics describing 
the centre of average of T2 or DTI scalar distributions (mean, median, mode or parametric 
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descriptions) was also not useful. Other distribution width and shape parameters were 
explored for T2, FA, MD, RD and AxD but the sole use of median absolute deviation was most 
effective and made a meaningful contribution to classifying groups. Given the typical width of 
T2 distributions in hippocampal subfields in a control and an aMCI patient (Figure 3), it is not 
surprising that a centre-point parameter is not useful.  
The z-scores for t-tests for all parameters are shown as boxplots (Figure S4). We found that 
classifiers using parameters from all subfields separately, as shown in the Figure 2 and Tables 
1 and 2, out-performed the use of the total hippocampal measures alone (not shown).   
Localising high-T2 voxels 
Given that the width of hippocampal subfield and EC T2 distributions and fractions of high-T2 
voxels, but not their centre-points or averages, have good group classifying power, we 
explored whether there was any regionalisation of high-T2 voxels in hippocampal subfields 
and the EC. This was performed in MNI space for the control, aMCI and ADD groups 
separately. Figure 4 shows that high-T2 regions are distributed more or less randomly 
throughout each subfield, but are more prevalent in the aMCI group relative to control group. 
Scatter plots of total hippocampal and EC volumes vs high-T2 fractions are given  (Figure S5), 
The highest high-T2 burden in the aMCI and ADD groups is in the EC, but this is not 
significantly higher than in any hippocampal subfield at the p < 0.05 level (Figure S6). The fact 
that the high-T2 regions are not in the proximity of outer hippocampal boundaries discounts 
the possibility that they are due to macroscopic partial volume effects with the CSF of the 
surrounding temporal horn. 
 
DISCUSSION  
We have shown that distributions of T2 profiles in the hippocampal subfields and EC are 
broader in aMCI and ADD patients than in control participants and that MD, RD and AxD differ 
also between the patients and controls. These observations support our first hypothesis of 
more heterogenous tissue microstructure in disease states than in cognitively normal aged 
controls in the medial temporal lobe structures. We also showed that quantitative MRI 
involving T2 relaxometry and DTI indices of the hippocampus and EC is better able to detect 
aMCI and ADD clinical states of the disease than the measurement of the respective volumes, 
and that their combination is superior to do so, in support to the second and third hypotheses. 
The finding that quantitative MRI of the hippocampus and EC is able to detect disease states 
implies that the MRI modalities chosen may indicate pathology associated with early ADD.  
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AD pathology is characterised by the appearance of amyloid 4 plaques and neurofibrillary 
tangles containing hyperphosphorylated tau. Although almost always present in the brain at 
some level, these are found at very much higher levels in ADD, and are associated with cell 
death and eventual atrophy (20). To what extent amyloid and/or tau pathology are causal of 
AD symptoms remains a topic of research and debate (31,32). Nonetheless, it is thought that 
the pathology of ADD develops (or begins to develop) very much sooner than clinical 
presentation or widespread neuronal cell death. AD pathology is generally first seen in the 
hippocampus and EC, before eventual spread through the medial temporal lobe and cortices 
(20,33). AD pathology is evident in the brains of majority of MCI patients (34). 
Both T2 relaxation time and DTI indices are descriptions of the heterogeneity of brain tissue. 
DTI indices have been used in assessment of hippocampal microstructure and 
microenvironment and shown to have ability to detect ADD-related pathology (9,11). The 
studies have shown decreased FA (11) and increased MD (9,11) in the body of hippocampus 
and these changes correlate with cognitive scores (9,11). In the current cohorts, elevated MD 
was observed. The previous studies (9,11) did not report sensitivity or specificity for FA or MD 
to separate controls from patients, however. The novelty of the current study includes 
quantification of tissue volume with fraction of high T2 relaxation time volume in hippocampal 
subfields indicative of a compromised functional state, parallel to the use of tissue type-specific 
T2. Our T2 MRI approach is much different from that used in previously, where T2 determined 
either in the whole hippocampus (18) or in ROIs within it (17,19,35) has been examined for its 
ability to separate cognitively healthy participants from either MCI (35) or ADD (18,19) patients 
with variable success. T2, as measured by a dual-echo spin echo sequence, has been 
reported to be either normal (17) or prolonged (18) in the hippocampus in ADD. T2 by a CPMG 
sequence has been found to be longer in the tail of right hippocampus in MCI (35) as well as 
in the head and the tail of right hippocampus in ADD (19,35) than in controls. We used a 
CPMG sequence and observed no difference in average hippocampal T2 times between 
controls, aMCI and ADD patients. Instead, Burr distributions of hippocampal subfield T2s were 
wider in both aMCI and ADD patients than in controls.  
Our findings from quantitative MRI metrics amount to the hippocampus and EC being more 
heterogeneous environments at a sub-voxel level in the progression to aMCI (and further to 
ADD), independently of the tissue quantity. A heterogeneous tissue environment has the 
implication that the cell count and/or viability are unlikely to be the same as in a healthy state. 
Water motility and quantity, implying the presence of structures impeding its motion or creating 
magnetic inhomogeneities (such as myelin sheaths and iron deposits) are unlikely to be the 
same in the aMCI and ADD states relative to controls. The increased presence of high-T2 
voxels in the aMCI and ADD patients imply more water (fewer cells) or more mobile water 
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(fewer barriers to water, such as cell membranes and dendrites). Macroscopic partial volume 
effects by CSF can be discounted, since the group-wise regionalisation shows no high-T2 
effects at hippocampal boundaries with surrounding CSF. The tissue heterogeneity, assessed 
by quantitative MRI, may therefore assess whether the tissue has entered a 
neurodegenerative state, in which tissue exists but with fewer intact cells per unit volume. 
Quantitative MRI markers of tissue heterogeneity were not strongly correlated with tissue 
volumes. This agrees with a previous study where no correlation with hippocampal volume 
and T2 was observed in ADD (35). Volume and heterogeneity may be considered near-
independent descriptors of a tissue, as hypothesised. The two categories of observations also 
had different group differences, volumes changing “step-wise” with group (control > aMCI > 
ADD), whilst tissue heterogeneity by any marker was significantly greater for aMCI and ADD 
than controls, but similar between aMCI and ADD. If aMCI commonly precedes the ADD state, 
this implies that increased tissue heterogeneity may precede volume loss. It has been reported 
that AD pathology is a very common finding in hippocampi of aMCI patients (34). The 
interpretation is that a neurodegenerative state precedes cell death – and, as hypothesised, 
may be detectable by MRI examination of tissue state by relaxometric and diffusion imaging 
of the hippocampus and EC (2). It is also interesting to note that the group differences in tissue 
heterogeneity markers, where measurable with subfield-specificity, show the largest effects in 
the EC, which is one of the earliest regions to be affected by AD pathology according to Braak 
staging (20). Histological examination of our participants at the time of scanning is impossible, 
but the correlation with known Braak staging is striking.  
EC has been implicated to very early AD by animal and human work using MRI of cerebral 
blood volume (CBV) (36). Neuropathological analyses of neuronal loss have shown cell death 
in CA1 (68%), subiculum (47%) and hilus (25%) in ADD patients (37). The loss of CA1 neurons 
is more severe in advanced than a mild ADD (38). Growing body of MRI data indicate that in 
MCI hippocampal atrophy is focal localising to CA1 and subiculum (39). Some studies report 
also more wide spread atrophy in MCI involving also CA3 and DG (39). It has been proposed, 
based on hippocampal shape analyses, that those MCI patients with atrophy of multiple 
subfields have heightened risk of conversion to ADD (40). Regarding EC, Khan et al. (36) 
studied mice harbouring APP-tau transgene as well as a human cohort that was followed for 
3.5 years for cognitive status. They reported selective dysfunction in participants converting 
to MCI in EC and parahippocampal gyrus, but not in the hippocampus. The drop in CBV was 
more pronounced in lateral EC compared to medial EC, indicating selective dysfunction of this 
structure in MCI converters, followed by a spread to precuneus and frontal brain (36). Reduced 
CBV was also evident in APP-tau transgenic mice, suggestive to involvement of these 
neurotoxic proteins in EC dysfunction. In the current study, we observed atrophy of multiple 
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hippocampal subfields in aMCI patients, including CA1, DG, subiculum, consistent with 
conclusion drawn in a recent review (39). Instead, no atrophy in EC was observed by us. We 
found no difference in either subfield or total hippocampal volumes between aMCI and ADD 
patients. Instead, the volume of EC was smaller in ADD than in MCI patients. 
Quantitative MRI data acquisition protocols are part of modern clinical MRI systems, for 
instance all MRI vendors provide clinical DTI and relaxometry sequence packages. 
Quantitative MRI protocols typically take 5-10 minutes longer to run than standard protocols 
for weighted images. Many of the image processing steps can be accomplished using free 
software, such as T2 fitting and hippocampal subfield segmentation. The ASHS procedure 
provider currently offers template atlases for healthy young and old adults, as well as aMCI 
patients. For other patient groups, such as ADD, sites may have to create their own atlases 
for use with ASHS. In-house programming is required for fitting the hippocampal subfield and 
EC T2 distributions, determining high-T2 fraction and their distributions in given structures. 
Our experience is that the described MRI protocol for hippocampal volumetry and tissue 
characterisation can be translated to clinical environment with modest efforts. 
Our study has certain limitations. First, cohorts of participants are imbalanced for their sizes, 
as the aMCI and ADD patients constituted only 39% of the total participant cohort. Both aMCI 
and ADD have complex neuropathology involving brain structures also outside medial 
temporal lobe regions studied here. However, hippocampus is affected in nearly 90% of ADD 
patients (8). Second, the study is cross-sectional. MR image characteristics and cognitive 
performance change with time, both of which could be determined by follow-up examinations. 
In conclusion, these data from modest cohorts of aMCI and ADD patients suggest that 
quantitative MRI could be better targeted to become a more sensitive marker of early ADD. 
We think this is an important area for future study to ensure cost effective improvement in 
early diagnosis of ADD such that interventions can be given at the right time.  
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 Table 1. Pairwise group comparisons of all MRI parameters. 
 
Vols CA1 CA3 DG SUB Total HC EC 
C / aMCI .001 K-W test 
not 
significant 
.004 .031 .003 .096* 
C / AD < .001 < .001 < .001 < .001 < .001* 
AD / aMCI 1.000 .535 .350 .710 .019* 
       
T2mad CA1 CA3 DG SUB Total HC EC 
C / aMCI < .001 < .001 .003 < .001 < .001 < .001* 
C / AD .006 < .001 .013 < .001 .001 < .001*  
AD / aMCI 1.000 1.000 1.000 1.000 1.000 .522* 
       
HighT2 CA1 CA3 DG SUB Total HC EC 
C / aMCI < .001 < .001 .011 < .001 < .001 < .001 
C / AD .005 .001 .015 < .001 .004 < .001 
AD / aMCI 1.000 1.000 1.000 1.000 1.000 1.000 
       
DTImad FA MD RD AxD   
C / aMCI K-W test 
not 
significant 
< .001 < .001 < .001   
C / AD < .001 < .001 < .001   
AD / aMCI .562 .723 .422   
       
Unless denoted by an asterisk (*), cells show p-values for Dunn’s post-hoc test following a 
significant Kruskal-Wallis (K-W) test for each subfield or DTI parameter. Asterisks (*) denote 
p-values calculated from ANOVA with Tukey’s post-hoc, as data in all three groups were 
normally distributed. Where K-W test was not significant, pairwise comparisons were not 
conducted. Bold values indicate P<0.05. Key: Abbreviations as defined in the text, Vols = 
volumes; Total HC = total hippocampal volume 
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Table 2. ROC statistics for SVM classifiers of cognitive group using different sets of 
observations.  
Set Set Group AUC σAUC TPR σTPR 1-FPR dFPR 
vols 1 C 92.7 7.9 93.6 13.8 90.5 7.4 
 
1 aMCI 75.6 15.5 70.0 34.0 82.2 13.5 
 
1 ADD 90.0 12.6 84.5 21.3 91.1 7.9 
T2mad 2 C 93.1 9.5 87.3 12.8 93.3 5.1 
 
2 aMCI 64.5 13.2 38.2 42.3 87.2 16.8 
 
2 ADD 65.5 26.1 57.4 43.0 86.6 12.2 
High-T2 3 C 94.6 4.2 90.6 8.5 93.6 5.6 
 
3 aMCI 77.1 12.5 62.6 33.5 85.2 13.9 
 
3 ADD 85.3 14.4 86.1 23.8 85.6 10.5 
DTImad 4 C 88.0 11.1 78.3 19.1 89.6 7.4 
 
4 aMCI 68.5 12.5 36.9 32.6 91.7 10.3 
 
4 ADD 81.7 10.6 64.3 19.2 90.4 8.8 
Cog 5 C 95.3 3.4 94.2 6.1 93.0 4.8 
 
5 aMCI 79.5 12.1 61.7 31.5 88.2 12.2 
 
5 ADD 89.6 5.0 87.5 8.1 90.7 6.6 
allMRI 1,2,3,4 C 95.2 6.6 98.4 9.4 93.1 7.8 
 
1,2,3,4 aMCI 81.0 17.4 79.0 32.2 85.6 12.1 
 
1,2,3,4 ADD 88.8 9.7 94.5 13.5 86.1 10.7 
best 1,3,5 C 97.5 6.9 99.2 6.7 97.0 6.7 
 
1,3,5 aMCI 82.2 15.3 87.7 23.9 83.2 12.3 
 
1,3,5 ADD 87.1 13.5 87.4 19.6 86.7 11.5 
 
AUC = area under curve, σAUC = standard deviation of AUC, TPR = true positive rate 
(sensitivity), σTPR = standard deviation of TPR, FPR = false positive rate (1-specificity). These 
are given as the mean of a group-balanced leave-out-one wrt smallest group procedure ± the 
standard deviation, as percentages. 
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Figure 1. Flowchart of T2 image data processing. CPMG multi-echo images are used to 
produce both echo-summed T2-weighted (T2-w) and absolute T2 images (T2 maps). T2-
weighted images are used together with T1-weighted MPRAGE images as inputs to the 
automated segmentation of hippocampal subfields (ASHS) to yield subfield masks. These 
subfield masks are transferred onto the T2 maps to produce subfield-specific T2 profiles. The 
T2 profiles are fitted to Burr function to identify normal and high T2 voxels in each subfield. 
The percentage of high T2 voxels is calculated for each subfield from these data. 
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Figure 2. ROC curves for the classification of aMCI and ADD groups using different sets of 
MRI and cognitive variables. Panel (a) shown ROC curves for hippocampal subfield and EC 
volume; panel (b) for T2mad; panel (c) for high T2 fractions; panel (d) for collective indices of 
DTImad; panel (e) for allMRI indices; panel (f) for cognitive tests, PAL and MoCA and panel 
(g) for combined MRI volumes, highT2 voxels and cognitive test.  
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Figure 3. Distributions of T2 within different hippocampal subfields for an aMCI participant 
aged 69 (top row) and a younger control participant aged 49 (bottom row). The increasing 
width and fraction of high-T2 voxels in the older MCI case is clear. The median, 20 ms lines, 
and the fit of a Burr distribution are shown in red. 
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Figure 4. Locations of high-T2 voxels at the 15% level (15% of participants in the group 
have a high-T2 value) in the Control (a,d. g, j) and aMCI (b, e, h, k) groups for selected 
subfields and the EC. The subfields are shown in cyan, the 15% probability high-T2 regions 
in red. Zoomed sections from the coronal image on the right show a slice through CA1 (c); 
dentate gyrus (f); subiculum (i) and entorhinal cortex (l).  
 
 
